

VIA EXPRESS MAIL

"Express Mail" mailing label

Number EI64203111US

Date of Deposit February 19, 2002

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under CFR 1.10 on the date indicated above, and is addressed to the Assistant Commissioner for Patents and Trademarks, BOX PCT Washington D.C. 20231

FULBRIGHT & JAWORSKI L.L.P.

Matthew J. Durst

SCHU-204.1 PFF/NDH (09902857)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s) : Dürst, Matthias and Nees, Matthias

Serial No. : Continuation of 09/308,984

Filed : Herewith

For : DNA For Evaluating The Progression Potential of Cervical Lesions

Group Art Unit : 1642

Examiner : J. Hunt

February 19, 2002

Hon. Commissioner of Patents
and Trademarks
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Prior to examination, please amend this application as follows:

IN THE SPECIFICATION

Page 1, prior to line, add: RELATED APPLICATION This application is a continuation of Serial No. 09/308/984, filed September 3, 1999, now US Patent--

line 1: change "DNA" to --nucleic acid molecules--

line 3: change "coded" to --encoded-- and "DNA" to --nucleic acid molecules--

line 5: change "DNA" to --nucleic acid molecules--

line 8: change "The invasive" to --Invasive--

line 14: change "higher" to --more severe--

line 29: change "discussed" to --known--

Page 2, line 15: change "of no significance" to --not useful--

line 17: change "progression" to --progressive--

lines 19-20: delete and replace by --This is the subject of the invention set forth in the disclosure which follows.--

line 22: change "a" to --an isolated-- after "acid" add --molecule--; change "progression" to --progressive--

line 23: after "acid" add --molecule--

line 24: change "provided" to --obtained--; change "favorable" to --preferred--

line 26: change "for" to --of--

line 33: change "to do" to --of doing--

line 34: change "can be" to --are--

Page 3, line 5: change "can be" to --are--

line 13: delete "a"

line 14: change "is called" to --are known as--

line 15: change "anchorage" to --anchor--

line 17: change "calculated" to --known--

line 19: delete "an"

line 22: change "anchorage" to --anchor--

line 23: delete "a"

line 28: change "above" to --round of--

line 30: change "sequence" to --sequences--

lines 36-37: delete and replace by

--Both cDNA and RNA are examples of nucleic acid molecules in accordance with the invention, with cDNA--

Page 4, line 9: after "acid" add --molecule--

line 12: change "and" to --or an--

line 14: change "are" to --include--

line 21: change "to" to --which--

line 22: delete "a"

Page 5, line 6: change "subject matter" to --feature--

line 7: change "An above polypeptide" to --A polypeptide in accordance with the invention--

line 10: change "subject matter" to --aspect--

line 13: change "and" to --an--

line 24: change "progression" to --progressive--

line 34: after "acid" add --molecule--; delete second "a"

Page 6, line 1: change "as usual" to --in accordance with known methods--

line 3: change "statement on" to --diagnosis of--

lines 5-6: change "suitable to take steps against the" to --useful for preventing--

line 9: after "acid" add --molecule--

line 10: delete "a"

line 11: after "acid" add --molecule--

line 12: change "expression inhibition" to --inhibition of expression--

line 17: change "acids" to --acid molecules--

line 19: change "acids" to --acid molecules--

line 23: change "below examples" to --examples which follow--

Page 7, line 6: delete "(see above)"

lines 7-8: delete "the RQ1 RNase-free DNase of PROMEGA having been used" and
replace by --using commercially available, RNase-free DNase purchased from PROMEGA--

line 9: delete "a"

line 10: delete "method"

lines 10-11: delete "what is called anchoring primers having been used as primers" and
replace by --using anchor primers, as are described supra--

Page 8, line 1: change ", ultimately" to --Ultimately,--

Page 9, line 7: change "comparison of" to --comparing--

Page 10, line 3: change "determined" to --sequenced--

line 4: delete "as regards their sequence"

line 15: change "It showed" to --The results indicated--

next to last line: delete "a"

IN THE CLAIMS

Amend claims 3, 4, 5, 8, 10 & 12 as follows:

Claim 3, line 1: delete "or 2".

Claim 4, line 1: delete "or 2"

Claim 5, line 2: delete "or 2"

Claim 12 (amended): Kit comprising at least one [or several] nucleic acid[s] molecule according to claim 1, [polypeptides according to claim 5 or 6 and/or antibodies according to claim 8] and (s well as) a conventional auxiliary agent[s].

Claim 13: Kit comprising at least one polypeptide according to claim 5, and a conventional auxiliary agent.

Claim 14: Kit comprising at least one antibody according to claim 8, and a conventional auxiliary agent.

REMARKS

Entry of the foregoing amendment is requested. Claims 1-14 will be pending.

Respectfully submitted,

FULBRIGHT & JAWORSKI L.L.P.

By 

Norman D. Hanson
Reg. No. 30,946

666 Fifth Avenue
New York, New York 10103
(212) 318-3000